BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

446 related articles for article (PubMed ID: 29759937)

  • 1. Identification of Epigenetic Regulators of DUX4-fl for Targeted Therapy of Facioscapulohumeral Muscular Dystrophy.
    Himeda CL; Jones TI; Virbasius CM; Zhu LJ; Green MR; Jones PL
    Mol Ther; 2018 Jul; 26(7):1797-1807. PubMed ID: 29759937
    [TBL] [Abstract][Full Text] [Related]  

  • 2. CRISPR/dCas9-mediated Transcriptional Inhibition Ameliorates the Epigenetic Dysregulation at D4Z4 and Represses DUX4-fl in FSH Muscular Dystrophy.
    Himeda CL; Jones TI; Jones PL
    Mol Ther; 2016 Mar; 24(3):527-35. PubMed ID: 26527377
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Sporadic DUX4 expression in FSHD myocytes is associated with incomplete repression by the PRC2 complex and gain of H3K9 acetylation on the contracted D4Z4 allele.
    Haynes P; Bomsztyk K; Miller DG
    Epigenetics Chromatin; 2018 Aug; 11(1):47. PubMed ID: 30122154
    [TBL] [Abstract][Full Text] [Related]  

  • 4. NuRD and CAF-1-mediated silencing of the D4Z4 array is modulated by DUX4-induced MBD3L proteins.
    Campbell AE; Shadle SC; Jagannathan S; Lim JW; Resnick R; Tawil R; van der Maarel SM; Tapscott SJ
    Elife; 2018 Mar; 7():. PubMed ID: 29533181
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Influence of
    Duranti E; Villa C
    Int J Mol Sci; 2023 May; 24(11):. PubMed ID: 37298453
    [TBL] [Abstract][Full Text] [Related]  

  • 6. A patient-derived iPSC model revealed oxidative stress increases facioscapulohumeral muscular dystrophy-causative DUX4.
    Sasaki-Honda M; Jonouchi T; Arai M; Hotta A; Mitsuhashi S; Nishino I; Matsuda R; Sakurai H
    Hum Mol Genet; 2018 Dec; 27(23):4024-4035. PubMed ID: 30107443
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Myogenic enhancers regulate expression of the facioscapulohumeral muscular dystrophy-associated DUX4 gene.
    Himeda CL; Debarnot C; Homma S; Beermann ML; Miller JB; Jones PL; Jones TI
    Mol Cell Biol; 2014 Jun; 34(11):1942-55. PubMed ID: 24636994
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Direct interplay between two candidate genes in FSHD muscular dystrophy.
    Ferri G; Huichalaf CH; Caccia R; Gabellini D
    Hum Mol Genet; 2015 Mar; 24(5):1256-66. PubMed ID: 25326393
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Transgenic mice expressing tunable levels of DUX4 develop characteristic facioscapulohumeral muscular dystrophy-like pathophysiology ranging in severity.
    Jones TI; Chew GL; Barraza-Flores P; Schreier S; Ramirez M; Wuebbles RD; Burkin DJ; Bradley RK; Jones PL
    Skelet Muscle; 2020 Apr; 10(1):8. PubMed ID: 32278354
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Intrinsic epigenetic regulation of the D4Z4 macrosatellite repeat in a transgenic mouse model for FSHD.
    Krom YD; Thijssen PE; Young JM; den Hamer B; Balog J; Yao Z; Maves L; Snider L; Knopp P; Zammit PS; Rijkers T; van Engelen BG; Padberg GW; Frants RR; Tawil R; Tapscott SJ; van der Maarel SM
    PLoS Genet; 2013 Apr; 9(4):e1003415. PubMed ID: 23593020
    [TBL] [Abstract][Full Text] [Related]  

  • 11. DICER/AGO-dependent epigenetic silencing of D4Z4 repeats enhanced by exogenous siRNA suggests mechanisms and therapies for FSHD.
    Lim JW; Snider L; Yao Z; Tawil R; Van Der Maarel SM; Rigo F; Bennett CF; Filippova GN; Tapscott SJ
    Hum Mol Genet; 2015 Sep; 24(17):4817-28. PubMed ID: 26041815
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Targeted epigenetic repression by CRISPR/dSaCas9 suppresses pathogenic
    Himeda CL; Jones TI; Jones PL
    Mol Ther Methods Clin Dev; 2021 Mar; 20():298-311. PubMed ID: 33511244
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Applying genome-wide CRISPR-Cas9 screens for therapeutic discovery in facioscapulohumeral muscular dystrophy.
    Lek A; Zhang Y; Woodman KG; Huang S; DeSimone AM; Cohen J; Ho V; Conner J; Mead L; Kodani A; Pakula A; Sanjana N; King OD; Jones PL; Wagner KR; Lek M; Kunkel LM
    Sci Transl Med; 2020 Mar; 12(536):. PubMed ID: 32213627
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Facioscapulohumeral Muscular Dystrophy: Update on Pathogenesis and Future Treatments.
    Hamel J; Tawil R
    Neurotherapeutics; 2018 Oct; 15(4):863-871. PubMed ID: 30361930
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Facioscapulohumeral muscular dystrophy.
    Tawil R
    Handb Clin Neurol; 2018; 148():541-548. PubMed ID: 29478599
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Transgenic Drosophila for Investigating DUX4 and FRG1, Two Genes Associated with Facioscapulohumeral Muscular Dystrophy (FSHD).
    Jones TI; Parilla M; Jones PL
    PLoS One; 2016; 11(3):e0150938. PubMed ID: 26942723
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Consequences of epigenetic derepression in facioscapulohumeral muscular dystrophy.
    Greco A; Goossens R; van Engelen B; van der Maarel SM
    Clin Genet; 2020 Jun; 97(6):799-814. PubMed ID: 32086799
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The Genetics and Epigenetics of Facioscapulohumeral Muscular Dystrophy.
    Himeda CL; Jones PL
    Annu Rev Genomics Hum Genet; 2019 Aug; 20():265-291. PubMed ID: 31018108
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Large family cohorts of lymphoblastoid cells provide a new cellular model for investigating facioscapulohumeral muscular dystrophy.
    Jones TI; Himeda CL; Perez DP; Jones PL
    Neuromuscul Disord; 2017 Mar; 27(3):221-238. PubMed ID: 28161093
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Protein kinase A activation inhibits
    Cruz JM; Hupper N; Wilson LS; Concannon JB; Wang Y; Oberhauser B; Patora-Komisarska K; Zhang Y; Glass DJ; Trendelenburg AU; Clarke BA
    J Biol Chem; 2018 Jul; 293(30):11837-11849. PubMed ID: 29899111
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 23.